Diane Cibrik, MD
Nephrology · Kansas City, KSNPI 1508948407
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,067 of the $11,887 with a category attached, or 76.3%. Sanofi-aventis U.S. LLC accounts for 71.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $8,355 and has fallen 74.4% since, to $2,142 in 2024.
Across 14 payments — averaging $849.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Calliditas Therapeutics US Inc.$3K
- Novartis$890
Across 4 payments — averaging $20,606 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$82K
What the payments were for
- Consulting fees$9,06776%
- Travel & lodging$2,44721%
- Food & beverage$3743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 7 | $8,497 |
| Calliditas Therapeutics US Inc. | 2 | $2,500 |
| Novartis | 5 | $890 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$8,373
- TARPEYO$2,500
How this compares
$11,887 in reported general payments places this provider in the 85th percentile of 55 nephrology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $21,880 |
| OzempicSemaglutide | 18 | $16,390 |
| Nifedipine ErNifedipine | 146 | $2,884 |
| Valganciclovir Hcl | 16 | $2,218 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $1,709 |
| Tacrolimus | 14 | $1,571 |
| Prednisone | 198 | $1,455 |
| Lisinopril | 218 | $1,098 |
| Losartan Potassium | 65 | $931 |
| Omeprazole | 57 | $739 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $685 |
| Famotidine | 70 | $635 |
| Budesonide DrBudesonide | 13 | $627 |
| Tamsulosin Hcl | 94 | $621 |
| Allopurinol | 33 | $508 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Kansas City
- Aditi GuptaKansas City$16K
- Alan YuKansas City$16K
- Ahmad TuffahaKansas City$15K
- Duncan JohnstoneKansas City$4K
- Amna IlaheKansas City$2K
- Sri YarlagaddaKansas City$1K
- Reem MustafaKansas City$1K
- Itunu OwoyemiKansas City$931
- Andrew StingoKansas City$637
- Venu NairKansas City$436
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.